China Pharmaceutical Industry Statistics For The First Five Months Of 2009
This article was originally published in PharmAsia News
Executive SummaryGuotai Junan Securities, a Chinese securities company, recently issued a report on the country's pharmaceutical industry statistics for the first five months of 2009. The industry's total revenue and profit respectively reached RMB 322 billion ($47 billion) and RMB 30.9 billion, growing 18 percent compared to the same period last year. The profit growth rate ranked fourth in the country's 11 consumer goods industries. In terms of different industry segments, the revenue of chemical raw materials, formulations, patent TCM, and biopharmaceuticals increased 5.57 percent, 25.9 percent, 16.7 percent and 12.6 percent, respectively. The two largest sectors - chemical formulations and TCM - enjoyed a strong performance; chemical raw materials and biopharmaceuticals showed average results; while hygiene materials, TCM slices and veterinary drugs saw rapid growth. (Click here for more - Chinese Language)
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.